News
ACRX
2.080
-5.45%
-0.120
5 Value Stocks In The Healthcare Sector
Benzinga · 5d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 01/27 13:06
Overview Of Value Stocks In The Healthcare Sector
Benzinga · 01/16 14:43
AcelRx announces $7.5M direct offering of common stock and warrants
Seekingalpha · 12/27/2022 14:15
BRIEF-Acelrx Announces $7.5 Mln Direct Offering Of Common Stock
Reuters · 12/27/2022 14:02
AcelRx Pharmaceuticals to Raise $7.5 Million via Securities Offering
AcelRx Pharmaceuticals to Raise $7.5 Million via Securities Offering
MT Newswires · 12/27/2022 11:01
Looking Into AcelRx Pharmaceuticals's Return On Capital Employed
Benzinga · 12/26/2022 14:48
AcelRx Says Study of Sufentanil Sublingual Tablets for Surgical Pain Management Shows Better Results Than Standard Therapy
AcelRx Says Study of Sufentanil Sublingual Tablets for Surgical Pain Management Shows Better Results Than Standard Therapy
MT Newswires · 12/08/2022 15:08
AcelRx Pharmaceuticals Highlights Publication Of Recent Retrospective Study Published In Journal of Clinical Medicine Titled 'Advances in Postoperative Pain Management and Postoperative Chronic Pain'
Benzinga · 12/08/2022 13:36
AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a recent retrospective study publis...
PR Newswire · 12/08/2022 13:30
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 12/07/2022 21:32
BRIEF-AcelRx Pharma Says, On Nov 29, Co Got Notice From Patheon Pharma That It Intends To Terminate Manufacturing Services Agreement Between Parties - Filing
Reuters · 12/05/2022 23:09
AcelRx Pharmaceuticals Received Notice From Patheon Pharmaceuticals Of Intent To Terminate Manufacturing Services Agreement Between Parties
Benzinga · 12/05/2022 22:29
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/21/2022 21:32
Sector Update: Health Care Stocks Fading in Late Tuesday Trading
Sector Update: Health Care Stocks Fading in Late Tuesday Trading
MT Newswires · 11/15/2022 15:57
Sector Update: Health Care Stocks Posting Small Advance
Sector Update: Health Care Stocks Posting Small Advance
MT Newswires · 11/15/2022 13:01
BRIEF-AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results, Provides Corporate Update
Reuters · 11/14/2022 21:45
AcelRx Pharmaceuticals GAAP EPS of -$0.94 beats by $0.26, revenue of $0.51M misses by $0.12M
Seekingalpha · 11/14/2022 21:02
-- Earnings Flash (ACRX) ACELRX PHARMACEUTICALS Reports Q3 Revenue $507,000, vs. Street Est of $0.625M
-- Earnings Flash (ACRX) ACELRX PHARMACEUTICALS Reports Q3 Revenue $507,000, vs. Street Est of $0.625M
MT Newswires · 11/14/2022 16:11
More
Webull provides a variety of real-time ACRX stock news. You can receive the latest news about Acelrx Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ACRX
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Its sufentanil sublingual products include DSUVIA, DZUVEO and Zalviso, which are focused on the treatment of moderate-to-severe acute pain in a medically supervised setting. Its pre-filled syringe product candidates include Ephedrine and Phenylephrine. Its nafamostat mesylate product candidates include Niyad, which is a regional anticoagulant for injection into the extracorporeal circuit, and LTX-608, which is a nafamostat formulation for antiviral treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), and acute pancreatitis.